Arbutus Biopharma Corp

Total Valuation

Arbutus Biopharma Corp carries a market capitalization of 892.87M, placing it among publicly traded companies globally. Its enterprise value stands at 771.05M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Arbutus Biopharma Corp currently has 196.95M shares outstanding.

Valuation Ratios

Arbutus Biopharma Corp trades at a trailing price-to-earnings ratio of 5.39. The price-to-sales ratio is 4.52, and the price-to-book ratio stands at 3.70.

Enterprise Valuation

The EV/Sales ratio of 4.03 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 4.97 provides insight into valuation relative to core operating earnings.

Financial Position

Arbutus Biopharma Corp maintains a current ratio of 54.26, meaning it holds 54.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.24, indicating conservative leverage, while an interest coverage ratio of 1,803.92 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Arbutus Biopharma Corp posts a return on equity of 115.07 and a return on invested capital of 90.92.

Stock Price Statistics

Arbutus Biopharma Corp's stock has gained approximately 43.94904% over the past 52 weeks. The 50-day moving average sits at 4.50, while the 200-day moving average is 4.45.

Income Statement

Over the trailing twelve months, Arbutus Biopharma Corp generated 191.45M in revenue and converted that into 160.72M in net income, yielding earnings per share of 0.83. EBITDA reached 155.14M, while operating income came in at 155.09M.

Balance Sheet

Arbutus Biopharma Corp holds 95.23M in cash and equivalents against 631,000.00 in total debt, resulting in a net debt position of -23.71M. Total book value stands at 234.12M, with working capital of 271.91M providing operational flexibility.

Cash Flow

Arbutus Biopharma Corp produced -34.36M in operating cash flow over the past twelve months.

Margins

Arbutus Biopharma Corp operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of 81.01 and net profit margin of 83.95 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Arbutus Biopharma Corp's most recent stock split took place on November 4, 2010 with a 5:1 split ratio.

Scores

Arbutus Biopharma Corp posts an Altman Z-Score of 28.18, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.